Entrada Therapeutics Inc (TRDA)
17.74
+0.14
(+0.82%)
USD |
NASDAQ |
Nov 04, 16:00
17.76
+0.01
(+0.06%)
After-Hours: 20:00
Entrada Therapeutics Research and Development Expense (Annual): 99.88M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 99.88M |
| December 31, 2022 | 66.61M |
| December 31, 2021 | 35.93M |
| Date | Value |
|---|---|
| December 31, 2020 | 21.10M |
| December 31, 2019 | 8.216M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.216M
Minimum
2019
99.88M
Maximum
2023
46.35M
Average
35.93M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Fulcrum Therapeutics Inc | 71.80M |
| Sarepta Therapeutics Inc | 877.39M |
| Catalyst Pharmaceuticals Inc | 93.15M |
| Vertex Pharmaceuticals Inc | 3.163B |
| Regenxbio Inc | 232.27M |